Drug intelligence / Profile preview

Debio 1348

Development stage: Unknown
Lead developer: Debiopharm
Administration: Oral

Overview

Debio 1348 is an investigational antibiotic program referenced by Debiopharm as part of its strategic expansion into novel antibacterial agents, but its detailed structure, target, spectrum of activity, and clinical development data have not been publicly disclosed. Available information only indicates that Debio 1348 is intended to represent a new class of antibiotics being developed in collaboration with external medicinal chemistry partners, without specifying whether it is a small molecule, peptide, or other modality, nor the bacterial pathways it targets.

Beyond the preview

Go deeper on Debio 1348.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Debio 1348.

Explore the full profile